Clinical Pharmacogenetic Testing and Application: Laboratory Medicine Clinical Practice Guidelines

참고문헌 (92)

1. 김솔잎, "임상약물유전학 검사와 적용: 진단검사의학 임상검사 지침 - 1부", Laboratory Medicine Online, 6(3), pp.119~133 (2016), 대한진단검사의학회
2. 김솔잎, "임상약물유전학 검사와 적용: 진단검사의학 임상검사 지침 - 2부", Laboratory Medicine Online, 6(4), pp.193~213 (2016), 대한진단검사의학회
3. Kim SY, "Manual for guideline adaptation ver 2.0", National evidence-based healthcare collaborating agency, ~ (2011)
4. Kim S, "Clinical pharmacogenetics testing and application: laboratory medicine clinical practice guidelines", The Korean Society of Laboratory Medicine, ~ (2016)
5. Johnson JA, "Clinical Pharmacogenetics Implementation Consortium Guidelines for CYP2C9 and VKORC1 genotypes and warfarin dosing", Clin Pharmacol Ther, 90, pp.625~629 (2011)
6. Scott SA, "Clinical Pharmacogenetics Implementation Consortium guidelines for cytochrome P450-2C19 (CYP2C19) genotype and clopidogrel therapy", Clin Pharmacol Ther, 90, pp.328~332 (2011)
7. Scott SA, "Clinical Pharmacogenetics Implementation Consortium guidelines for CYP2C19 genotype and clopidogrel therapy: 2013 update", Clin Pharmacol Ther, 94, pp.317~323 (2013)
8. Crews KR, "Clinical Pharmacogenetics Implementation Consortium (CPIC) guidelines for codeine therapy in the context of cytochrome P450 2D6 (CYP2D6) genotype", Clin Pharmacol Ther, 91, pp.321~326 (2012)
9. Crews KR, "Clinical Pharmacogenetics Implementation Consortium guidelines for cytochrome P450 2D6 genotype and codeine therapy: 2014 update", Clin Pharmacol Ther, 95, pp.376~382 (2014)
10. Hicks JK, "Clinical Pharmacogenetics Implementation Consortium guideline for CYP2D6 and CYP2C19 genotypes and dosing of tricyclic antidepressants", Clin Pharmacol Ther, 93, pp.402~408 (2013)
11. Relling MV, "Clinical pharmacogenetics implementation consortium guidelines for thiopurine methyltransferase genotype and thiopurine dosing: 2013 update", Clin Pharmacol Ther, 93, pp.324~325 (2013)
12. Relling MV, "Clinical Pharmacogenetics Implementation Consortium guidelines for thiopurine methyltransferase genotype and thiopurine dosing", Clin Pharmacol Ther, 89, pp.387~391 (2011)
13. Swen JJ, "Pharmacogenetics: from bench to byte--an update of guidelines", Clin Pharmacol Ther, 89, pp.662~673 (2011)
14. Valdes R, "Laboratory analysis and application of pharmacogenetics to clinical practice" (2010), National Academy of Clinical Biochemistry
15. Gammal RS, "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for UGT1A1 and Atazanavir Prescribing", Clin Pharmacol Ther, 99, pp.363~369 (2016)
16. Cai Y, "Pharmacogenetic study of drug-metabolising enzyme polymorphisms on the risk of anti-tuberculosis drug-induced liver injury: a meta-analysis", PLoS One, 7, pp.e47769~ (2012)
17. Lindeman NI, "Molecular testing guideline for selection of lung cancer patients for EGFR and ALK tyrosine kinase inhibitors: guideline from the College of American Pathologists, International Association for the Study of Lung Cancer, and Association for Molecular Pathology", J Mol Diagn, 15, pp.415~453 (2013)
18. "NCCN clinical practice guidelines in oncology. Colon Cancer. Version 2" (2014)[URL]
19. Wolff AC, "American Society of Clinical Oncology", College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer, 2007, pp.25, 118~145
20. Wolff AC, "Recommendations for human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology", College of American Pathologists clinical practice guideline update, 2013, pp.31, 3997~4013
21. Wolff AC, "Recommendations for human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology", College of American Pathologists clinical practice guideline update, 2014, pp.138, 241~256
22. Theriault RL, "Breast cancer, version 3.2013: featured updates to the NCCN guidelines", J Natl Compr Canc Netw, 11, pp.753~760 (2013)
23. Albanell J, "Guidelines for HER2 testing in breast cancer: a national consensus of the Spanish Society of Pathology (SEAP) and the Spanish Society of Medical Oncology (SEOM)", Clin Transl Oncol, 11, pp.363~375 (2009)
24. Bartlett JM, "HER2 testing in the UK: recommendations for breast and gastric in-situ hybridisation methods", J Clin Pathol, 64, pp.649~653 (2011)
25. Morton RF, "ASCO Provisional Clinical Opinion: KRAS, Cetuximab, and Panitumumab-Clinical Implications in Colorectal Cancer", J Oncol Pract, 5, pp.71~72 (2009)
26. Van Cutsem E, "Advanced colorectal cancer: ESMO Clinical Practice Guidelines for treatment", Ann Oncol, 21(S5), pp.v93~v97 (2010)
27. Becquemont L, "Practical recommendations for pharmacogenomics-based prescription: 2010 ESF-UB Conference on Pharmacogenetics and Pharmacogenomics", Pharmacogenomics, 12, pp.113~124 (2011)
28. Normanno N, "KRAS mutations testing in colorectal carcinoma patients in Italy: from guidelines to external quality assessment", PLoS One, 6, pp.e29146~ (2011)
29. García-Alfonso P, "Guidelines for biomarker testing in colorectal carcinoma (CRC): a national consensus of the Spanish Society of Pathology (SEAP) and the Spanish Society of Medical Oncology (SEOM)", Clin Transl Oncol, 14, pp.726~739 (2012)
30. Higashi MK, "Association between CYP2C9 genetic variants and anticoagulation-related outcomes during warfarin therapy", JAMA, 287, pp.1690~1698 (2002)
31. Jacobs LG, "Warfarin pharmacology, clinical management, and evaluation of hemorrhagic risk for the elderly", Clin Geriatr Med, 22, pp.17~32 (2006)
32. Rieder MJ, "Effect of VKORC1 haplotypes on transcriptional regulation and warfarin dose", N Engl J Med, 352, pp.2285~2293 (2005)
33. Lee CR, "Cytochrome P450 2C9 polymorphisms: a comprehensive review of the in-vitro and human data", Pharmacogenetics, 12, pp.251~263 (2002)
34. Limdi NA, "Warfarin pharmacogenetics: a single VKORC1 polymorphism is predictive of dose across 3 racial groups", Blood, 115, pp.3827~3834 (2010)
35. Aithal GP, "Association of polymorphisms in the cytochrome P450 CYP2C9 with warfarin dose requirement and risk of bleeding complications", Lancet, 353, pp.717~719 (1999)
36. Limdi NA, "Influence of CYP2C9 and VKORC1 1173C", T genotype on the risk of hemorrhagic complications in African-American and European-American patients on warfarin, 2008, pp.83, 312~321
37. Lindh JD, "Influence of CYP2C9 genotype on warfarin dose requirements--a systematic review and meta-analysis", Eur J Clin Pharmacol, 65, pp.365~375 (2009)
38. Rost S, "Mutations in VKORC1 cause warfarin resistance and multiple coagulation factor deficiency type 2", Nature, 427, pp.537~541 (2004)
39. Ross KA, "Worldwide allele frequency distribution of four polymorphisms associated with warfarin dose requirements", J Hum Genet, 55, pp.582~589 (2010)
40. Wajih N, "Increased production of functional recombinant human clotting factor IX by baby hamster kidney cells engineered to overexpress VKORC1, the vitamin K 2,3-epoxide-reducing enzyme of the vitamin K cycle", J Biol Chem, 280, pp.31603~31607 (2005)
41. Yuan HY, "A novel functional VKORC1 promoter polymorphism is associated with inter-individual and inter-ethnic differences in warfarin sensitivity", Hum Mol Genet, 14, pp.1745~1751 (2005)
42. Wadelius M, "Common VKORC1 and GGCX polymorphisms associated with warfarin dose", Pharmacogenomics J, 5, pp.262~270 (2005)
43. Gage BF, "Use of pharmacogenetic and clinical factors to predict the therapeutic dose of warfarin", Clin Pharmacol Ther, 84, pp.326~331 (2008)
44. International Warfarin Pharmacogenetics Consortium, "Estimation of the warfarin dose with clinical and pharmacogenetic data", N Engl J Med, 360, pp.753~764 (2009)
45. Finkelman BS, "Genetic warfarin dosing: tables versus algorithms", J Am Coll Cardiol, 57, pp.612~618 (2011)
46. Nunnelee JD, "Review of an Article: The international Warfarin Pharmacogenetics Consortium (2009). Estimation of the warfarin dose with clinical and pharmacogenetic data. NEJM 360 (8): 753-64", J Vasc Nurs, 27, pp.109~ (2009)
47. Nowak-Göttl U, "In pediatric patients, age has more impact on dosing of vitamin K antagonists than VKORC1 or CYP2C9 genotypes", Blood, 116, pp.6101~6105 (2010)
48. Lenzini P, "Integration of genetic, clinical, and INR data to refine warfarin dosing", Clin Pharmacol Ther, 87, pp.572~578 (2010)
49. Mega JL, "Reduced-function CYP2C19 genotype and risk of adverse clinical outcomes among patients treated with clopidogrel predominantly for PCI: a meta-analysis", JAMA, 304, pp.1821~1830 (2010)
50. Harmsze A, "Besides CYP2C19*2, the variant allele CYP2C9*3 is associated with higher on-clopidogrel platelet reactivity in patients on dual antiplatelet therapy undergoing elective coronary stent implantation", Pharmacogenet Genomics, 20, pp.18~25 (2010)
51. Hwang SJ, "The cytochrome 2C19*2 and *3 alleles attenuate response to clopidogrel similarly in East Asian patients undergoing elective percutaneous coronary intervention", Thromb Res, 127, pp.23~28 (2011)
52. Xie X, "CYP2C19 phenotype, stent thrombosis, myocardial infarction, and mortality in patients with coronary stent placement in a Chinese population", PLoS One, 8, pp.e59344~ (2013)
53. Jeong YH, "Effect of CYP2C19*2 and *3 loss-of-function alleles on platelet reactivity and adverse clinical events in East Asian acute myocardial infarction survivors treated with clopidogrel and aspirin", Circ Cardiovasc Interv, 4, pp.585~594 (2011)
54. 박경진, "Clinical, Pharmacokinetic, and Pharmacogenetic Determinants of Clopidogrel Resistance in Korean Patients with Acute Coronary Syndrome", Annals of Laboratory Medicine, 31(2), pp.91~94 (2011), 대한진단검사의학회
55. Lee JM, "Relation of genetic polymorphisms in the cytochrome P450 gene with clopidogrel resistance after drug-eluting stent implantation in Koreans", Am J Cardiol, 104, pp.46~51 (2009)
56. Depta JP, "Antiplatelet therapy and proton pump inhibition: cause for concern?", Curr Opin Cardiol, 27, pp.642~650 (2012)
57. Shehab N, "National estimates of emergency department visits for hemorrhage-related adverse events from clopidogrel plus aspirin and from warfarin", Arch Intern Med, 170, pp.1926~1933 (2010)
58. 박형석, "Association between Genetic Polymorphisms of CYP2D6 and Outcomes in Breast Cancer Patients with Tamoxifen Treatment", Journal of Korean Medical Science, 26(8), pp.1007~1013 (2011), 대한의학회
59. Gaedigk A, "Optimization of cytochrome P4502D6 (CYP2D6) phenotype assignment using a genotyping algorithm based on allele frequency data", Pharmacogenetics, 9, pp.669~682 (1999)
60. Gaedigk A, "The CYP2D6 activity score: translating genotype information into a qualitative measure of phenotype", Clin Pharmacol Ther, 83, pp.234~242 (2008)
61. Dezentjé VO, "CYP2D6 genotype- and endoxifen-guided tamoxifen dose escalation increases endoxifen serum concentrations without increasing side effects", Breast Cancer Res Treat, 153, pp.583~590 (2015)
62. Irvin WJ, Jr., "Genotype-guided tamoxifen dosing increases active metabolite exposure in women with reduced CYP2D6 metabolism: a multicenter study", J Clin Oncol, 29, pp.3232~3239 (2011)
63. Kim SH, "Genetic polymorphisms of drug-metabolizing enzymes and anti-TB drug-induced hepatitis", Pharmacogenomics, 10, pp.1767~1779 (2009)
64. Bozok Cetintaş V, "Determining the relation between N-acetyltransferase-2 acetylator phenotype and antituberculosis drug induced hepatitis by molecular biologic tests", Tuberk Toraks, 56, pp.81~86 (2008)
65. Lee SW, "NAT2 and CYP2E1 polymorphisms and susceptibility to first-line anti-tuberculosis drug-induced hepatitis", Int J Tuberc Lung Dis, 14, pp.622~626 (2010)
66. "Human NAT2 Alleles (Haplotypes)"[URL]
67. Bertrand J, "Dependence of efavirenz- and rifampicin-isoniazid-based antituberculosis treatment drug-drug interaction on CYP2B6 and NAT2 genetic polymorphisms: ANRS 12154 study in Cambodia", J Infect Dis, 209, pp.399~408 (2014)
68. Lee SY, "Complete sequencing of a genetic polymorphism in NAT2 in the Korean population", Clin Chem, 48, pp.775~777 (2002)
69. Lee KM, "N-acetyltransferase (NAT1, NAT2) and glutathione S-transferase (GSTM1, GSTT1) polymorphisms in breast cancer", Cancer Lett, 196, pp.179~186 (2003)
70. Azuma J, "NAT2 genotype guided regimen reduces isoniazid-induced liver injury and early treatment failure in the 6-month four-drug standard treatment of tuberculosis: a randomized controlled trial for pharmacogenetics-based therapy", Eur J Clin Pharmacol, 69, pp.1091~1101 (2013)
71. Cho HJ, "Genetic polymorphisms of NAT2 and CYP2E1 associated with antituberculosis drug-induced hepatotoxicity in Korean patients with pulmonary tuberculosis", Tuberculosis (Edinb), 87, pp.551~556 (2007)
72. Jung JA, "A proposal for an individualized pharmacogenetic-guided isoniazid dosage regimen for patients with tuberculosis", Drug Des Devel Ther, 9, pp.5433~5438 (2015)
73. Peloquin CA, "Therapeutic drug monitoring in the treatment of tuberculosis", Drugs, 62, pp.2169~2183 (2002)
74. Um SW, "Low serum concentrations of anti-tuberculosis drugs and determinants of their serum levels", Int J Tuberc Lung Dis, 11, pp.972~978 (2007)
75. Etienne-Grimaldi MC, "UGT1A1 genotype and irinotecan therapy: general review and implementation in routine practice", Fundam Clin Pharmacol, 29, pp.219~237 (2015)
76. Sim SC, "Pharmacogenomics of drug-metabolizing enzymes: a recent update on clinical implications and endogenous effects", Pharmacogenomics J, 13, pp.1~11 (2013)
77. Han FF, "Associations between UGT1A1*6 or UGT1A1*6", *28 polymorphisms and irinotecan-induced neutropenia in Asian cancer patients, 2014, pp.73, 779~788
78. Cheng L, "UGT1A1*6 polymorphisms are correlated with irinotecan-induced toxicity: a system review and meta-analysis in Asians", Cancer Chemother Pharmacol, 73, pp.551~560 (2014)
79. Ki CS, "Haplotype structure of the UDP-glucuronosyltransferase 1A1 (UGT1A1) gene and its relationship to serum total bilirubin concentration in a male Korean population", Clin Chem, 49, pp.2078~2081 (2003)
80. Park WB, "Genetic factors influencing severe atazanavir-associated hyperbilirubinemia in a population with low UDP-glucuronosyltransferase 1A1*28 allele frequency", Clin Infect Dis, 51, pp.101~106 (2010)
81. Choi YH, "A Phase II study of clinical outcomes of 3-week cycles of irinotecan and S-1 in patients with previously untreated metastatic colorectal cancer: influence of the UGT1A1 and CYP2A6 polymorphisms on clinical activity", Oncology, 82, pp.290~297 (2012)
82. Kim KP, "A UGT1A1*28 and *6 genotype-directed phase I dose-escalation trial of irinotecan with fixed-dose capecitabine in Korean patients with metastatic colorectal cancer", Cancer Chemother Pharmacol, 71, pp.1609~1617 (2013)
83. Benkov K, "Role of thiopurine metabolite testing and thiopurine methyltransferase determination in pediatric IBD", J Pediatr Gastroenterol Nutr, 56, pp.333~340 (2013)
84. Lennard L, "The clinical pharmacology of 6-mercaptopurine", Eur J Clin Pharmacol, 43, pp.329~339 (1992)
85. Evans WE, "Preponderance of thiopurine S-methyltransferase deficiency and heterozygosity among patients intolerant to mercaptopurine or azathioprine", J Clin Oncol, 19, pp.2293~2301 (2001)
86. Appell ML, "Nomenclature for alleles of the thiopurine methyltransferase gene", Pharmacogenet Genomics, 23, pp.242~248 (2013)
87. Kim HY, "Complete sequence-based screening of TPMT variants in the Korean population", Pharmacogenet Genomics, 25, pp.143~146 (2015)
88. Turner D, "Management of pediatric ulcerative colitis: joint ECCO and ESPGHAN evidence-based consensus guidelines", J Pediatr Gastroenterol Nutr, 55, pp.340~361 (2012)
89. De Roock W, "Association of KRAS p.G13D mutation with outcome in patients with chemotherapy-refractory metastatic colorectal cancer treated with cetuximab", JAMA, 304, pp.1812~1820 (2010)
90. Tejpar S, "Association of KRAS G13D tumor mutations with outcome in patients with metastatic colorectal cancer treated with first-line chemotherapy with or without cetuximab", J Clin Oncol, 30, pp.3570~3577 (2012)
91. Neumann J, "Frequency and type of KRAS mutations in routine diagnostic analysis of metastatic colorectal cancer", Pathol Res Pract, 205, pp.858~862 (2009)
92. Whirl-Carrillo M, "Pharmacogenomics knowledge for personalized medicine", Clin Pharmacol Ther, 92, pp.414~417 (2012)

관련 논문AI추천